Month: November 2022

On January 18, 2017, Jimenez, Jacqueline; Lopez, Mildred; Carranza, Vladimir; Mendoza, Angel; Varela, Jenaro; Sansinenea, Estibaliz; Ortiz, Aurelio published an article.Recommanded Product: (S)-4-Isopropyl-5,5-dimethyloxazolidin-2-one The title of the article was Diastereoselective hydrogenation of α,β-unsaturated but-2-enamides to access the chiral 3-(p-tolyl)butanoic acids. And the article contained the following:

An alternative methodol. for the synthesis of chiral 3-(p-tolyl)butanoic acids is presented. This was accomplished through the diastereoselective hydrogenation reaction of different chiral N-3-(p-tolyl)but-2-enamides, using Pd/C in EtOH, to produce the corresponding chiral N-3-(p-tolyl)butanamides, e.g., I with high chem. yields and moderate diastereomeric ratios. Removal of the chiral auxiliary from N-3-(p-tolyl)butanamides gave the resp. enantiomerically pure acids. The experimental process involved the reaction of (S)-4-Isopropyl-5,5-dimethyloxazolidin-2-one(cas: 168297-86-7).Recommanded Product: (S)-4-Isopropyl-5,5-dimethyloxazolidin-2-one

The Article related to butanoic acid preparation diastereoselective, unsaturated butenamide hydrogenation, Benzene, Its Derivatives, and Condensed Benzenoid Compounds: Amides, Amidines, Imidic Esters, Hydrazides, and Hydrazonic Esters and other aspects.Recommanded Product: (S)-4-Isopropyl-5,5-dimethyloxazolidin-2-one

Referemce:
Oxazolidine – Wikipedia,
Oxazolidine | C3H7NO – PubChem

On August 31, 2013, Claridge, Timothy D. W.; Davies, Stephen G.; Kruchinin, Dennis; Odell, Barbara; Roberts, Paul M.; Russell, Angela J.; Thomson, James E.; Toms, Steven M. published an article.Computed Properties of 168297-86-7 The title of the article was Solution phase structures of enantiopure and racemic lithium N-benzyl-N-(α-methylbenzyl)amide in THF: low temperature 6Li and 15N NMR spectroscopic studies. And the article contained the following:

The antipodes of lithium N-benzyl-N-(α-methylbenzyl)amide are highly efficient enantiopure ammonia equivalent for the asym. synthesis of β-amino acid derivatives via conjugate addition to α,β-unsaturated esters. 6Li and 15N NMR spectroscopic studies of doubly labeled 6lithium (S)-15N-benzyl-15N-(α-methylbenzyl)amide in THF at low temperature reveal the presence of lithium amide dimers as the only observable species. Either a monomeric or dimeric lithium amide reactive species can be accommodated within the transition state mnemonic for this class of conjugate addition reaction. This enantiopure lithium amide offers unique opportunities over achiral (e.g., lithium dibenzylamide) and C2-sym. (e.g., lithium bis-N,N-α-methylbenzylamide) counterparts for further mechanistic study owing to the ready distinction of the various dimers formed. The experimental process involved the reaction of (S)-4-Isopropyl-5,5-dimethyloxazolidin-2-one(cas: 168297-86-7).Computed Properties of 168297-86-7

The Article related to solution phase structure enantiopure racemate lithium benzylmethylbenzylamide nmr, Physical Organic Chemistry: Resonance Spectra (Electron Spin, Nuclear Magnetic and Fourier Transform Nuclear Magnetic, Quadrupole, etc.) and other aspects.Computed Properties of 168297-86-7

Referemce:
Oxazolidine – Wikipedia,
Oxazolidine | C3H7NO – PubChem

On August 4, 2011, Hoffmann, Matthias; Dahmann, Georg; Fiegen, Dennis; Handschuh, Sandra; Klicic, Jasna; Linz, Guenter; Schaenzle, Gerhard; Schnapp, Andreas; East, Stephen P.; Mazanetz, Michael Philip; Scott, John; Walker, Edward published a patent.COA of Formula: C4H7NO3 The title of the patent was Preparation of substituted naphthyridines and their use as therapeutic Syk kinase inhibitors. And the patent contained the following:

The invention relates to new substituted naphthyridines of formula I, as well as pharmacol. acceptable salts, diastereomers, enantiomers, racemates, hydrates or solvates thereof, wherein R1 is -O-R3 or -NR3R4, R3 is substituted C1-6-alkyl, R4 is H or C1-6-alkyl, and R2 is H, (un)substituted 5-10-membered aryl, (un)substituted 5-10-membered heteroaryl, etc., as well as pharmaceutical compositions containing these compounds Naphthyridines of formula I are particularly suitable for the treatment of respiratory complaints, allergic diseases, osteoporosis, gastrointestinal diseases, autoimmune diseases, inflammatory diseases and diseases of the peripheral or central nervous system, particularly for the treatment of asthma, allergic rhinitis, rheumatoid arthritis, allergic dermatitis and COPD. Synthetic procedures for preparing I are exemplified. Example compound II, prepared by reacting (R)-4-((R)-1-hydroxyethyl)pyrrolidine-2-one and III, had an IC50 of 0.0131 μM in an Syk kinase luminescence assay. The experimental process involved the reaction of (R)-5-(Hydroxymethyl)oxazolidin-2-one(cas: 97859-49-9).COA of Formula: C4H7NO3

The Article related to preparation naphthyridine syk kinase inhibitor therapy, Heterocyclic Compounds (More Than One Hetero Atom): Fused-Ring Systems With Two Or More Hetero Atoms, No More Than One Hetero Atom Per Ring and other aspects.COA of Formula: C4H7NO3

Referemce:
Oxazolidine – Wikipedia,
Oxazolidine | C3H7NO – PubChem